| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6113587 | Critical Reviews in Oncology/Hematology | 2016 | 8 Pages |
Abstract
Other TAs improve PFS but not OS when compared to sorafenib. The use of sorafenib in patients with an intermediate prognosis, especially in second-line therapy, does not have a detrimental effect on PFS and might be an option for certain patients.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Roberto Iacovelli, Elena Verri, Maria Cossu Rocca, Gaetano Aurilio, Daniela Cullurà , Matteo Santoni, Ottavio de Cobelli, Franco Nolé,